HUS2200053I1 - HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek - Google Patents
HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületekInfo
- Publication number
- HUS2200053I1 HUS2200053I1 HUS2200053C HUS2200053C HUS2200053I1 HU S2200053 I1 HUS2200053 I1 HU S2200053I1 HU S2200053 C HUS2200053 C HU S2200053C HU S2200053 C HUS2200053 C HU S2200053C HU S2200053 I1 HUS2200053 I1 HU S2200053I1
- Authority
- HU
- Hungary
- Prior art keywords
- therapeutic
- preventive
- virus infection
- compounds suitable
- hiv virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377312P | 2016-08-19 | 2016-08-19 | |
| US201762457555P | 2017-02-10 | 2017-02-10 | |
| EP17758388.7A EP3347352B1 (en) | 2016-08-19 | 2017-08-17 | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUS2200053I1 true HUS2200053I1 (hu) | 2023-01-28 |
Family
ID=59714166
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17758388A HUE045137T2 (hu) | 2016-08-19 | 2017-08-17 | HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek |
| HUE19178148A HUE063811T2 (hu) | 2016-08-19 | 2017-08-17 | HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek |
| HUS2200053C HUS2200053I1 (hu) | 2016-08-19 | 2022-12-14 | HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17758388A HUE045137T2 (hu) | 2016-08-19 | 2017-08-17 | HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek |
| HUE19178148A HUE063811T2 (hu) | 2016-08-19 | 2017-08-17 | HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek |
Country Status (43)
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI853404B (zh) | 2016-08-19 | 2024-08-21 | 美商基利科學股份有限公司 | 治療性化合物 |
| AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TW202024061A (zh) * | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AU2019221568B2 (en) | 2018-02-15 | 2021-04-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating HIV infection |
| TWI823164B (zh) | 2018-02-16 | 2023-11-21 | 美商基利科學股份有限公司 | 用於製備有療效化合物之方法及中間物 |
| US20210115061A1 (en) * | 2018-06-21 | 2021-04-22 | Drexel University | Small-Molecule HIV-1 Capsid Protein Inhibitors and Methods Using Same |
| TWI814350B (zh) * | 2018-07-16 | 2023-09-01 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| US11958834B2 (en) | 2018-08-09 | 2024-04-16 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP7361766B2 (ja) | 2018-09-14 | 2023-10-16 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP7433303B2 (ja) | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| MY207622A (en) * | 2018-10-22 | 2025-03-06 | Univ Nebraska | Antiviral prodrugs and nanoformulations thereof |
| JP7532354B2 (ja) * | 2018-10-24 | 2024-08-13 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| PL3870577T3 (pl) | 2018-10-24 | 2025-06-16 | VIIV Healthcare UK (No.5) Limited | Inhibitory replikacji ludzkiego wirusa niedoboru odporności |
| PT3870575T (pt) | 2018-10-25 | 2023-05-12 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| EP3873607B1 (en) | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| JP2022509919A (ja) * | 2018-11-05 | 2022-01-25 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| WO2020095176A1 (en) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UA128041C2 (uk) | 2019-01-25 | 2024-03-20 | Браун Юніверсіті | Спосіб лікування пов'язаного з віком запалення у пацієнта |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| PL3938047T3 (pl) | 2019-03-22 | 2022-11-07 | Gilead Sciences, Inc. | Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne |
| JP7545414B2 (ja) | 2019-04-30 | 2024-09-04 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | ヒト免疫不全ウイルス複製阻害剤 |
| RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| MX2021016149A (es) * | 2019-06-19 | 2022-05-18 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de inmunodeficiencia humana. |
| US20220389007A1 (en) | 2019-10-01 | 2022-12-08 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| ES2974657T3 (es) * | 2019-10-01 | 2024-07-01 | Viiv Healthcare Uk No 5 Ltd | Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20220370451A1 (en) | 2019-10-08 | 2022-11-24 | VIIV HEALTHCARE UK ( No. 5) LIMITED | Inhibitors of human immunodeficiency virus replication |
| EP4065116B1 (en) * | 2019-11-26 | 2026-01-21 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
| CN114929685B (zh) * | 2019-11-29 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 稠合吡啶环衍生物、其制备方法及其在医药上的应用 |
| CN116098917A (zh) * | 2020-02-27 | 2023-05-12 | 河南真实生物科技有限公司 | 核苷类化合物在治疗冠状病毒感染性疾病中的用途 |
| KR20220151655A (ko) | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| EP4114527A1 (en) | 2020-03-06 | 2023-01-11 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| KR20220156884A (ko) | 2020-03-20 | 2022-11-28 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| JP7799620B2 (ja) | 2020-04-15 | 2026-01-15 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| TWI858267B (zh) | 2020-06-25 | 2024-10-11 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20230107288A (ko) | 2020-11-11 | 2023-07-14 | 길리애드 사이언시즈, 인코포레이티드 | gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법 |
| AU2022211056A1 (en) | 2021-01-25 | 2023-07-20 | Brii Biosciences, Inc. | Combination therapy for hiv with adenosine derivative and capsid inhibitors |
| WO2022247942A1 (zh) * | 2021-05-28 | 2022-12-01 | 江苏恒瑞医药股份有限公司 | 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 |
| KR20230018690A (ko) | 2021-07-30 | 2023-02-07 | (주) 에빅스젠 | 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물 |
| KR20230019059A (ko) | 2021-07-30 | 2023-02-07 | (주) 에빅스젠 | 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물 |
| JP2024535596A (ja) * | 2021-10-13 | 2024-09-30 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | ヒト免疫不全ウイルス複製の阻害薬 |
| CA3237155A1 (en) | 2021-12-03 | 2023-06-08 | Zhimin Du | Therapeutic compounds for hiv virus infection |
| AU2022403012B2 (en) * | 2021-12-03 | 2026-02-12 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| SI4440702T1 (sl) | 2021-12-03 | 2025-09-30 | Gilead Sciences, Inc. | Terapevtske spojine za okužbo z virusom hiv |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20240034724A1 (en) | 2022-07-01 | 2024-02-01 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| CN119768183A (zh) | 2022-08-26 | 2025-04-04 | 吉利德科学公司 | 用于广泛中和抗体的给药和安排方案 |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| KR20240061218A (ko) | 2022-10-31 | 2024-05-08 | 주식회사 이보드 | 복합 단열재 및 제조방법 |
| EP4658663A2 (en) | 2023-01-30 | 2025-12-10 | Merck Sharp & Dohme LLC | Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors |
| AR132464A1 (es) | 2023-04-19 | 2025-07-02 | Gilead Sciences Inc | Régimen de dosificación de inhibidor de la cápside |
| WO2024249592A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Quinazolinyl-indazole derivatives as therapeutic compounds for hiv |
| US20250011353A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Process of preparing hiv capsid inhibitor |
| AU2024281548A1 (en) | 2023-05-31 | 2025-11-13 | Gilead Sciences, Inc. | Solid forms of compounds useful in the treatment of hiv |
| CN116675675A (zh) * | 2023-06-05 | 2023-09-01 | 北京康立生医药技术开发有限公司 | 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法 |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| TW202513072A (zh) | 2023-08-15 | 2025-04-01 | 美商基利科學股份有限公司 | 比替拉韋及利那卡帕韋之醫藥配方 |
| EP4529922A1 (en) | 2023-09-29 | 2025-04-02 | Gilead Sciences, Inc. | Pharmaceutical formulations of bictegravir and lenacapavir |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| KR20250040288A (ko) | 2023-09-15 | 2025-03-24 | 민영호 | 복합 단열재 |
| US20250120989A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202530227A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202530226A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025169059A1 (en) | 2024-02-05 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250367386A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240393A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240389A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240385A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367384A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025264995A1 (en) * | 2024-06-21 | 2025-12-26 | Gilead Sciences, Inc. | Formulations of an hiv capsid inhibitor |
| WO2026006521A1 (en) | 2024-06-27 | 2026-01-02 | Gilead Sciences, Inc. | Oral tablet formulations |
| WO2026020086A1 (en) | 2024-07-19 | 2026-01-22 | Gilead Sciences, Inc. | Methods and pharmaceutical formulations for treating viral infections |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| CA2083386C (en) | 1990-06-13 | 1999-02-16 | Arnold Glazier | Phosphorous prodrugs |
| ATE167679T1 (de) | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| NZ535408A (en) | 2000-07-21 | 2006-09-29 | Gilead Sciences Inc | Method for selecting prodrugs of phosphonate nucleotide analogues |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| EP1399420B1 (en) | 2001-06-27 | 2007-12-05 | SmithKline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| DE60218511T2 (de) | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| US20040186151A1 (en) | 2003-02-12 | 2004-09-23 | Mjalli Adnan M.M. | Substituted azole derivatives as therapeutic agents |
| US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| BRPI0508186A (pt) | 2004-02-27 | 2007-08-14 | Schering Corp | compostos como inibidores de ns3 serina protease de vìrus da hepatite c |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| ES2720618T3 (es) | 2004-07-27 | 2019-07-23 | Gilead Sciences Inc | Análogos de fosfonato de compuestos de inhibidores de VIH |
| US8067587B2 (en) | 2005-07-28 | 2011-11-29 | Lenroc Company | Process for the production of monoalkali metal cyanurates |
| CN101268077A (zh) | 2005-08-05 | 2008-09-17 | 阿斯利康(瑞典)有限公司 | 三环苯并咪唑及其作为代谢型谷氨酸受体调节剂的用途 |
| ATE511502T1 (de) | 2005-12-14 | 2011-06-15 | Bristol Myers Squibb Co | Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren |
| DK2010493T3 (en) | 2006-04-12 | 2016-05-02 | Merck Sharp & Dohme | PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS |
| US7647464B2 (en) | 2006-04-28 | 2010-01-12 | At&T Intellectual Property, I,L.P. | Methods, systems, and products for recording media to a restoration server |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8124811B2 (en) | 2007-03-20 | 2012-02-28 | Allylix, Inc. | Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one |
| CN101702908A (zh) | 2007-03-23 | 2010-05-05 | 麻萨诸塞州大学 | Hiv-1蛋白酶抑制剂 |
| CN101801925A (zh) | 2007-06-29 | 2010-08-11 | 吉里德科学公司 | 抗病毒组合物 |
| RU2498979C2 (ru) | 2007-07-12 | 2013-11-20 | Тиботек Фармасьютикалз | Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила |
| JP5433573B2 (ja) | 2007-07-19 | 2014-03-05 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | 抗ウイルス剤としての大環状化合物 |
| CA2701594C (en) | 2007-10-24 | 2014-02-18 | Merck Sharp & Dohme Corp. | Heterocycle phenyl amide t-type calcium channel antagonists |
| US20100249176A1 (en) | 2007-10-24 | 2010-09-30 | Barrow James C | Heterocycle amide t-type calcium channel antagonists |
| US8354429B2 (en) | 2007-11-16 | 2013-01-15 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| JP5537442B2 (ja) | 2008-03-13 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | 第ｘｉａ因子阻害剤としてのピリダジン誘導体 |
| NZ612380A (en) | 2008-12-09 | 2015-01-30 | Gilead Sciences Inc | Modulators of toll-like receptors |
| KR20110118176A (ko) | 2009-02-25 | 2011-10-28 | 빅텍 프라이빗 리미티드 | 치쿤군야의 검출을 위한 프로브 및 프라이머 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| TWI453208B (zh) | 2010-07-02 | 2014-09-21 | Gilead Sciences Inc | 治療性化合物類 |
| AP2013006707A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CN103702561B (zh) | 2011-03-23 | 2017-02-22 | 特维娜有限公司 | 阿片样物质受体配体以及使用和制备其的方法 |
| EP3181555B1 (en) | 2011-04-21 | 2018-11-28 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AP3639A (en) | 2011-08-16 | 2016-03-13 | Gilead Sciences Inc | Tenofovir alafenamide hemifumarate |
| JP6144698B2 (ja) | 2011-12-20 | 2017-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｉｖ複製の阻害剤としての縮合三環式化合物 |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| WO2014028931A2 (en) | 2012-08-17 | 2014-02-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| ME02400B (me) | 2012-12-21 | 2016-09-20 | Gilead Sciences Inc | Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba |
| EP2940019B1 (en) | 2012-12-27 | 2018-03-28 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| NZ631762A (en) | 2013-01-09 | 2017-02-24 | Gilead Sciences Inc | 5-membered heteroaryls and their use as antiviral agents |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) * | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| MX2016004492A (es) | 2013-10-24 | 2016-06-16 | Squibb Bristol Myers Co | Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih). |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| JP6491321B2 (ja) | 2014-08-29 | 2019-03-27 | ギリアード サイエンシーズ， インコーポレイテッド | 抗レトロウイルス剤 |
| WO2016040084A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| ES2735087T3 (es) | 2014-12-24 | 2019-12-16 | Gilead Sciences Inc | Compuestos de pirimidina fusionados para el tratamiento de VIH |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| UY36648A (es) | 2015-04-23 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| CA2983162A1 (en) | 2015-04-23 | 2016-10-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| HRP20190853T1 (hr) * | 2015-07-06 | 2019-06-28 | Gilead Sciences, Inc. | Cot modulatori i postupci za njihovu upotrebu |
| US10171985B1 (en) | 2015-07-22 | 2019-01-01 | Ginko LLC | Method and apparatus for data sharing |
| TWI853404B (zh) | 2016-08-19 | 2024-08-21 | 美商基利科學股份有限公司 | 治療性化合物 |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| UY37710A (es) | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| AU2019221568B2 (en) | 2018-02-15 | 2021-04-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating HIV infection |
| TWI823164B (zh) | 2018-02-16 | 2023-11-21 | 美商基利科學股份有限公司 | 用於製備有療效化合物之方法及中間物 |
| US10911396B2 (en) | 2018-06-28 | 2021-02-02 | Paypal, Inc. | Mid-tier messaging system |
| TWI814350B (zh) | 2018-07-16 | 2023-09-01 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| EP4065116B1 (en) | 2019-11-26 | 2026-01-21 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| TWI858267B (zh) | 2020-06-25 | 2024-10-11 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
-
2017
- 2017-08-17 TW TW112100805A patent/TWI853404B/zh active
- 2017-08-17 LT LTEP19178148.3T patent/LT3597646T/lt unknown
- 2017-08-17 CN CN202010662665.4A patent/CN111793061B/zh active Active
- 2017-08-17 TW TW108108262A patent/TWI715944B/zh active
- 2017-08-17 HK HK18116015.7A patent/HK1256904B/en unknown
- 2017-08-17 KR KR1020207032788A patent/KR20200131351A/ko not_active Ceased
- 2017-08-17 KR KR1020237000165A patent/KR20230011471A/ko not_active Ceased
- 2017-08-17 HR HRP20231018TT patent/HRP20231018T1/hr unknown
- 2017-08-17 TW TW109146483A patent/TW202138365A/zh unknown
- 2017-08-17 KR KR1020197007456A patent/KR102180740B1/ko active Active
- 2017-08-17 SI SI201731404T patent/SI3597646T1/sl unknown
- 2017-08-17 MA MA42795A patent/MA42795B1/fr unknown
- 2017-08-17 EP EP17758388.7A patent/EP3347352B1/en active Active
- 2017-08-17 HU HUE17758388A patent/HUE045137T2/hu unknown
- 2017-08-17 SG SG11201808944QA patent/SG11201808944QA/en unknown
- 2017-08-17 JP JP2019508953A patent/JP6716785B2/ja active Active
- 2017-08-17 BR BR112018071678-2A patent/BR112018071678B1/pt active Search and Examination
- 2017-08-17 ES ES17758388T patent/ES2746374T3/es active Active
- 2017-08-17 SI SI201730077T patent/SI3347352T1/sl unknown
- 2017-08-17 DK DK19178148.3T patent/DK3597646T3/da active
- 2017-08-17 PE PE2019000375A patent/PE20190910A1/es unknown
- 2017-08-17 LT LTEP17758388.7T patent/LT3347352T/lt unknown
- 2017-08-17 HU HUE19178148A patent/HUE063811T2/hu unknown
- 2017-08-17 UA UAA201901739 patent/UA121630C2/uk unknown
- 2017-08-17 EP EP19178148.3A patent/EP3597646B1/en active Active
- 2017-08-17 US US15/680,041 patent/US10071985B2/en active Active
- 2017-08-17 KR KR1020247014103A patent/KR20240070646A/ko not_active Ceased
- 2017-08-17 PE PE2020000548A patent/PE20211427A1/es unknown
- 2017-08-17 PT PT191781483T patent/PT3597646T/pt unknown
- 2017-08-17 FI FIEP19178148.3T patent/FI3597646T3/fi active
- 2017-08-17 BR BR122020001791-0A patent/BR122020001791B1/pt active IP Right Grant
- 2017-08-17 PL PL17758388T patent/PL3347352T3/pl unknown
- 2017-08-17 TW TW113111532A patent/TW202504608A/zh unknown
- 2017-08-17 CN CN201780063636.2A patent/CN109890808B/zh active Active
- 2017-08-17 EP EP23179840.6A patent/EP4265299A3/en active Pending
- 2017-08-17 DK DK17758388.7T patent/DK3347352T3/da active
- 2017-08-17 ES ES19178148T patent/ES2954514T3/es active Active
- 2017-08-17 CN CN202411603090.3A patent/CN119462611A/zh active Pending
- 2017-08-17 AU AU2017312102A patent/AU2017312102B2/en active Active
- 2017-08-17 MA MA050673A patent/MA50673A/fr unknown
- 2017-08-17 PL PL19178148.3T patent/PL3597646T3/pl unknown
- 2017-08-17 WO PCT/US2017/047416 patent/WO2018035359A1/en not_active Ceased
- 2017-08-17 MY MYPI2019000877A patent/MY191466A/en unknown
- 2017-08-17 UY UY0001037367A patent/UY37367A/es not_active Application Discontinuation
- 2017-08-17 CR CR20190084A patent/CR20190084A/es unknown
- 2017-08-17 PT PT17758388T patent/PT3347352T/pt unknown
- 2017-08-17 SG SG10201912535VA patent/SG10201912535VA/en unknown
- 2017-08-17 KR KR1020257017413A patent/KR20250085838A/ko active Pending
- 2017-08-17 PH PH1/2021/552802A patent/PH12021552802A1/en unknown
- 2017-08-17 NZ NZ750706A patent/NZ750706A/en unknown
- 2017-08-17 MX MX2018012905A patent/MX369307B/es active IP Right Grant
- 2017-08-17 CA CA3021227A patent/CA3021227C/en active Active
- 2017-08-17 TW TW106127987A patent/TWI664966B/zh active
-
2018
- 2018-06-25 US US16/016,718 patent/US10654827B2/en active Active
- 2018-12-16 JO JOP/2018/0123A patent/JOP20180123A1/ar unknown
-
2019
- 2019-02-04 IL IL264644A patent/IL264644B/en active IP Right Grant
- 2019-02-15 CL CL2019000415A patent/CL2019000415A1/es unknown
- 2019-02-15 CO CONC2019/0001379A patent/CO2019001379A2/es unknown
- 2019-02-15 EC ECSENADI201911209A patent/ECSP19011209A/es unknown
- 2019-02-15 PH PH12019500335A patent/PH12019500335A1/en unknown
- 2019-02-15 DO DO2019000033A patent/DOP2019000033A/es unknown
- 2019-02-18 SA SA519401123A patent/SA519401123B1/ar unknown
- 2019-03-07 ZA ZA2019/01430A patent/ZA201901430B/en unknown
- 2019-09-13 CY CY20191100958T patent/CY1122296T1/el unknown
- 2019-11-25 US US16/694,332 patent/US11993583B2/en active Active
-
2020
- 2020-03-18 JP JP2020048130A patent/JP2020111592A/ja not_active Withdrawn
- 2020-04-02 AU AU2020202331A patent/AU2020202331C1/en active Active
- 2020-10-19 JP JP2020175151A patent/JP2021008516A/ja active Pending
-
2021
- 2021-08-26 AU AU2021221855A patent/AU2021221855B2/en active Active
-
2022
- 2022-10-27 JP JP2022172416A patent/JP2023011754A/ja not_active Withdrawn
- 2022-12-13 LU LU00292C patent/LUC00292I2/fr unknown
- 2022-12-14 HU HUS2200053C patent/HUS2200053I1/hu unknown
- 2022-12-16 FR FR22C1063C patent/FR22C1063I2/fr active Active
- 2022-12-16 NO NO2022059C patent/NO2022059I1/no unknown
- 2022-12-22 CY CY2022039C patent/CY2022039I1/el unknown
-
2023
- 2023-01-05 LT LTPA2023501C patent/LTC3347352I2/lt unknown
- 2023-01-11 NL NL301212C patent/NL301212I2/nl unknown
- 2023-11-27 AU AU2023271739A patent/AU2023271739B2/en active Active
-
2024
- 2024-04-11 US US18/632,593 patent/US20240376077A1/en active Pending
- 2024-08-30 JP JP2024148326A patent/JP2024170471A/ja active Pending
-
2025
- 2025-11-21 AU AU2025271141A patent/AU2025271141A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200053I1 (hu) | HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek | |
| FI3684377T3 (fi) | Menetelmiä hepatiitti b -infektion hoitamiseksi | |
| IL284255A (en) | 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection | |
| IL258822A (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| IL280769A (en) | New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection | |
| PL3346995T3 (pl) | Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności | |
| PL3504214T3 (pl) | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami | |
| LT3436074T (lt) | Tiazolido junginiai, skirti virusinių infekcijų gydymui | |
| DK3471732T3 (da) | Liposomer til behandling af virusinfektioner | |
| ZA201900770B (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| EP3768681A4 (en) | INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION | |
| LT3504210T (lt) | Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai |